Cytokinetics Heart Drug Scores in Closely Watched Trial

Cytokinetics' Myqorzo Succeeds in Phase 3 Non-Obstructive HCM Trial

Cytokinetics announced positive Phase 3 trial results for its drug Myqorzo in people with non-obstructive hypertrophic cardiomyopathy (HCM). The drug met its dual primary endpoints, demonstrating statistically significant improvements in peak oxygen consumption and heart health assessment scores compared to placebo over 36 weeks. Myqorzo also hit key secondary measures, with no new safety signals identified. This success positions Myqorzo to address a significant unmet need in non-obstructive HCM, a market where rival therapy Camzyos previously failed, and opens up a multibillion-dollar market opportunity for Cytokinetics.

• Myqorzo achieved statistically significant improvements in both primary endpoints. Patients treated with Myqorzo showed an increase of 0.64 ml/kg/min in peak oxygen consumption, while placebo recipients saw a decline of 0.03 ml/kg/min. Additionally, Myqorzo led to an approximately 11-point improvement on the KCCQ Clinical Summary Score, a patient-reported measure of symptoms and physical limitations, compared to an 8-point increase in the placebo group over 36 weeks.
• The Phase 3 trial reported no new safety signals for Myqorzo, with patient completion rates similar between treatment and placebo groups. While drops in left ventricular ejection fraction (LVEF) over 50% occurred in 27 Myqorzo recipients versus one in the placebo group, leading to treatment interruption for 3% of participants, the overall profile was considered favorable. This outcome differentiates Myqorzo from Bristol Myers Squibb's Camzyos, which failed in non-obstructive HCM, highlighting Myqorzo's potential in this specific patient population.
• The positive trial results are expected to significantly boost Cytokinetics' market value, with analysts estimating potential peak global sales exceeding $5 billion annually if approved for both obstructive and non-obstructive HCM. Cytokinetics plans to engage with regulators to discuss the study findings and present the data at an upcoming medical meeting, signaling a clear path towards potential market authorization and addressing a long-standing need for new treatments in this condition.

Myqorzo's Phase 3 Triumph in Non-Obstructive HCM

The triple-crossover randomized controlled trial comparing beta-blocker (bisoprolol) versus calcium-channel blocker (verapamil) in nonobstructive hypertrophic cardiomyopathy represents a landmark study in this therapeutic area. This 2026 double-blinded, placebo-controlled trial enrolled 32 patients with nonobstructive HCM and at least one marker of disease severity, comparing target doses of 7.5 mg bisoprolol, 360 mg verapamil, and placebo over 2-week treatment periods. The primary efficacy endpoint demonstrated that bisoprolol significantly reduced peak oxygen consumption (pVO₂) compared to both verapamil (-1.8 mL/kg/min, P = 0.013) and placebo (-2.5 mL/kg/min, P = 0.002), while verapamil showed no significant difference from placebo. Both active treatments reduced peak heart rate compared to placebo, with bisoprolol showing a more pronounced effect (-37 beats/min) than verapamil (-17 beats/min).

The myocardial function and biomarker profiles revealed divergent therapeutic effects between the two interventions. Verapamil improved global longitudinal strain by -1.1% (P = 0.001) compared to placebo and significantly reduced NT-proBNP levels by -177 ng/L (P < 0.001), suggesting favorable cardiac remodeling effects. In contrast, bisoprolol showed no improvement in global longitudinal strain and actually increased NT-proBNP levels by +165 ng/L (P = 0.006) compared to placebo. Additionally, bisoprolol demonstrated concerning structural changes including increased left atrial volume index (+13.0 mL/m², P < 0.001) and elevated tricuspid regurgitation pressure gradient (+4.3 mm Hg, P = 0.049), while verapamil showed no such adverse structural effects.

The hybrid cardiac telerehabilitation study and exercise meta-analysis provide complementary evidence for non-pharmacological interventions in nonobstructive HCM. The 12-week supervised telerehabilitation program in 60 patients demonstrated significant improvement in peak oxygen uptake (+1.35 mL/kg/min, P < 0.01) with high adherence rates and no serious adverse events reported. The systematic review and meta-analysis encompassing 2,217 HCM patients across 8 studies confirmed that structured exercise programs improve cardiorespiratory fitness (+1.76 mL/kg/min in VO₂ peak, P < 0.0001) without increasing major adverse cardiac events risk (RR 1.01, P = 0.97), supporting the integration of supervised exercise training into clinical management protocols for carefully selected low-risk patients.

Myqorzo's Breakthrough: A New Horizon for Non-Obstructive HCM

The recent announcement of positive Phase 3 results for Cytokinetics' Myqorzo in non-obstructive hypertrophic cardiomyopathy (nHCM) marks a pivotal moment for patients and the pharmaceutical industry. Hypertrophic cardiomyopathy (HCM) is a complex, often inherited condition characterized by hypercontractility and impaired relaxation of the heart, with current treatments largely focused on symptom management rather than addressing the underlying disease mechanism. While cardiac myosin inhibitors (CMIs) like mavacamten have transformed the treatment landscape for obstructive HCM (oHCM), the non-obstructive form has remained a significant unmet need, lacking targeted therapeutic options.

Myqorzo's success in demonstrating statistically significant improvements in key endpoints like peak oxygen consumption and heart health assessment scores is a direct challenge to this therapeutic void. This positions Myqorzo as a potential first-in-class approved therapy for nHCM, a market segment where mavacamten previously showed no discernible benefit in trials. This breakthrough not only validates the CMI mechanism for a broader spectrum of HCM but also opens up a substantial new market opportunity for Cytokinetics.

However, the path forward is not without considerations. As with other CMIs, the potential for transient reductions in left ventricular ejection fraction (LVEF) will require vigilant monitoring and careful dose titration in clinical practice. Furthermore, while Myqorzo appears to be leading the charge, emerging data from other CMIs, such as aficamten's promising 36-week results in nHCM, suggest that competition in this newly validated space may intensify. Finally, the generalizability of trial results to the diverse real-world nHCM patient population, often more complex than those in highly selected clinical cohorts, will be crucial for Myqorzo's long-term success and broad adoption.